Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H1 2018

  • ID: 4473084
  • Report
  • 74 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Athenex Inc
  • Basilea Pharmaceutica Ltd
  • Pfizer Inc
  • MORE
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H1 2018

Summary:

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR).

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipeline Target constitutes close to 14 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Immunology and Infectious Disease which include indications Breast Cancer, Melanoma, High-Grade Glioma, Ovarian Cancer, Solid Tumor, Actinic (Solar) Keratosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Arrhythmias, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Esophageal Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lung Adenocarcinoma, Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Mild Cognitive Impairment, Myocardial Infarction, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Osteosarcoma, Peritoneal Cancer, Prostate Cancer, Psoriasis, Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Skin Cancer, Small-Cell Lung Cancer, Stroke, Thrombosis, Thymoma (Thymic Epithelial Tumor) and Thyroid Cancer.

The latest report Tyrosine Protein Kinase CSK - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics
Reasons to Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Athenex Inc
  • Basilea Pharmaceutica Ltd
  • Pfizer Inc
  • MORE
Introduction

Report Coverage

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

Athenex Inc

Basilea Pharmaceutica Ltd

Pfizer Inc

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Drug Profiles

apatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bosutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-196969 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-241161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eCF-506 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit c-Src Tyrosine Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit C Src Kinase for Colon Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Src Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit CSK for Stroke and Thrombosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UM-164 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Feb 20, 2018: Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting

Feb 14, 2018: Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis

Dec 20, 2017: LSKB Announces Enrollment of the First Patients in the US and Europe for its Ongoing Apatinib Phase 3 Clinical Trial in Advanced or Metastatic Gastric Cancer

Dec 19, 2017: U.S. FDA Approves Pfizer’s BOSULIF (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)

Dec 10, 2017: LSKB Announces its Clinical Initiative to Study the Safety and Efficacy of Cancer Therapies Combining Apatinib with Immunotherapy

Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting

Sep 25, 2017: Athenex Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis

Aug 29, 2017: U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Bosulif (Bosutinib) for the Treatment of Patients With Newly Diagnosed Ph+ Chronic Myeloid Leukemia

Aug 24, 2017: Cancer Drug May Benefit Patients With Inherited Form Of Kidney Disease

Jun 19, 2017: The US FDA Grants Apatinib Orphan Drug Designation for Treatment of Gastric Cancer

May 24, 2017: Athenex and Its Partner, Guangzhou Xiangxue Pharmaceutical, Announced Chinese FDA IND Approval to Begin Clinical Trials of KX-02 Tablet for Glioblastoma

May 16, 2017: LSK Biopharma Announces Starting of Site Initiation Visits in the U.S. for its Phase 3 Gastric Cancer Trial Studying Apatinib

May 08, 2017: Lsk Biopharma Announces Approval to Initiate a Phase 2 Clinical Trial in Colorectal Cancer in South Korea

Mar 13, 2017: LSK BioPharma Announces Enrollment of First Patient in Phase 3 Apatinib Trial in Gastric Cancer

Mar 01, 2017: LSK BioPharmas Apatinib Receives Orphan Drug Designation in the European Union

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Advenchen Laboratories LLC, H1 2018

Pipeline by Athenex Inc, H1 2018

Pipeline by Basilea Pharmaceutica Ltd, H1 2018

Pipeline by Pfizer Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Advenchen Laboratories LLC
  • Athenex Inc
  • Basilea Pharmaceutica Ltd
  • Pfizer Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll